Gritstone Oncology, the two-year-old Emeryville startup that develops immunotherapy treatments for cancer, has received $93 million in new financing, the company announced Thursday. The privately held company is one of several Bay Area startups making inroads in applying artificial intelligence to drug discovery, a fast-growing segment of the health technology field that has attracted hundreds of millions of dollars from investors over the last few years.